Large Volume Parenteral Market Size, Share, Opportunities, And Trends By Volume (100 ml - 250 ml, 250 ml - 500 ml, Above 500 ml), By Application (Correction of Electrolyte & Fluid Balance Disturbances, Nutrition, Vehicle for Administering Other Drugs), By Packaging Container (Glass Bottle, Plastic Bags), And By Geography- Forecasts From 2025 To 2030

The large volume parenteral market is expected to grow at a CAGR of 5.05%, reaching a market size of US$15.843 billion in 2030 from US$12.385 billion in 2025.

Parenterals are dosage forms that are not administered orally; drug administration is done by alternative routes, including intramuscular, subcutaneous, and intravenous. Large-volume parenteral (LVP) is administered intravenously and has a volume of more than 100ml. These include 100 mL, 250 mL, 500 mL, 1000 mL, and 2000 mL. As a result, they are packaged in large quantities for use in several applications, including nourishment, electrolyte and fluid balance correction, and medication administration.

What are the large volume parenteral market drivers?

• The increasing prevalence of chronic diseases is contributing to the large volume parenteral market’s expansion

The prevalence of hospitalizations per year for disorders requiring LVPs is expected to drive the market during the forecast period. LVPs are widely used in surgeries; consequently, the increasing number of surgical procedures is also driving market expansion throughout the projection period.

Moreover, common large-volume parenteral include sodium chloride solution, dextrose solution, Ringer's solution, lactated Ringer's solution, and a mixture of dextrose and sodium chloride. LVPs serve as a way of speedier medicine administration for patients in need, notably during surgeries, and are quite effective. Further, the rising medicine delivery sector also gives tremendous growth opportunities for the market to expand during the forecast period. The rising demand among patients for single-dose vaccination delivery is also driving market expansion throughout the predicted period.

• Increased cases of heart diseases are anticipated to increase the market expansion

The growing number of patients diagnosed with heart disease is one of the primary drivers of this parenteral market. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) kill 17.9 million people each year, accounting for around 31% of all deaths globally. Increased tobacco use, a poor diet, and physical inactivity all increase the risk of heart attack and stroke. The Centers for Disease Control and Prevention report that heart disease is the leading cause of mortality in the United States, with coronary heart disease being the most frequent form.

Moreover, large-volume parenterals are used in cardiac surgery to prevent myocardial ischemia during blood flow to the heart. LVPs are also utilized to maintain a bloodless operating field and to make myocardial flaccid, as they are electrolytic solutions with a composition designed to maintain diastolic arrest. As a result, these methods necessitate providing cold to chill the heart and reduce activity. The solutions are somewhat alkaline and hypertonic, and they are utilized to compensate for metabolic acidosis while also decreasing reperfusion harm caused by tissue edema.

• The growing need for therapeutic injections is also increasing the market expansion

Therapeutic injections are types of injections that go right inside the joint, primarily to alleviate swelling and pain. It is well known that therapeutic injections are often prescribed for patients suffering from chronic joint pains after they have been through all possible treatments, including physical therapies. Rheumatoid arthritis, osteoarthritis, and other pain-related ailments will likely drive this therapeutic injection segment growth during the forecast period. This is mainly because the number of patients suffering from these disorders is increasing, and the dependence on therapeutic injection for pain is also rising due to its instant effectiveness and benefits.

Further, an increase in research studies also supports interesting findings around pain management and the use of therapeutic injections, which is likely to drive the category growth during this research period. Therapeutic and corticosteroid injections, combined with an anesthetic numbing agent to lessen joint pain and inflammation, are among the most widely used.

The large volume parenteral market is analyzed into the following segments:

• By packaging container, glass packaging is anticipated to grow during the forecast period

Extensive use of generic injectable medications, combined with strong demand from the pharmaceutical sector, is expected to drive market expansion. Glasses generally consist of limestone (CaCO3), soda ash (Na2CO3), cullet, and sand (SiO2). Moreover, transformations in cost-sensitive and biotechnological medications are causing harsh regulations on technologies for drug delivery in the healthcare sector. Major manufacturers in the pharmaceutical glass-making industry are concentrating on such packaging that would ultimately increase the shelf life of a product and are thus turning their attention to investment in vials.

Geographical outlook of the large volume parenteral market:

• North America is witnessing exponential growth during the forecast period.

Owing to its strong healthcare infrastructure and a great deal of pain-associated disorders, North America will gain a significant market share over the projected period by increasing the use of LVPs. In addition, the increase in surgeries is expected to support market growth along with the fluid replacement therapies that are going on throughout North America during the projected period.

Further, LVP is used as it can continuously deliver a specific drug, usually morphine, through a catheter into the intraspinal space for a patient who has pain from cancer. For instance, the American Cancer Society estimates that there will be 2,001,140 new cancer cases and 611,720 cancer deaths in the US in 2024.

Key launches in the large volume parenteral market:

• In April 2024: Upperton Pharma Solutions has established a new production facility in Nottingham, UK, to develop parenteral packaging solutions, including small-volume parenterals. The new site, located at the recently opened Trent Gateway Business Park in Beeston, will significantly expand the company's capabilities in terms of capacity and scale of manufacture, with the addition of ten new GMP manufacturing suites, Quality Control laboratories, and dedicated Analytical and Formulation Development laboratories with pilot plant facilities.

Large volume parenteral market scope:

Report Metric	Details
Large Volume Parenteral Market Size in 2025	US$12.385 billion
Large Volume Parenteral Market Size in 2030	US$15.843 billion
Growth Rate	CAGR of 5.05%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Volume Application Packaging Container Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Large Volume Parenteral Market	Fresenius Kabi AG Albert David Ltd. Otsuka Holdings Co., Ltd. Grifols S.A. B. Braun Melsungen AG
Customization Scope	Free report customization with purchase

 

The large volume parenteral market is segmented and analyzed as follows:

• By Volume
  • 100 ml - 250 ml
  • 250 ml - 500 ml
  • Above 500 ml
• By Application
  • Correction of electrolyte & fluid balance disturbances
  • Nutrition
  • Vehicle for administering other drugs
• By Packaging Container
  • Glass Bottle
  • Plastic Bags
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
    • UAE
    • Israel
    • Saudi Arabia
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View 

5.  LARGE VOLUME PARENTERAL MARKET BY VOLUME

5.1. Introduction

5.2. 100 ml - 250 ml

5.3. 250 ml - 500 ml

5.4. Above 500 ml

6.  LARGE VOLUME PARENTERAL MARKET BY APPLICATION

6.1. Introduction

6.2. Correction of electrolyte & fluid balance disturbances

6.3. Nutrition

6.4. Vehicle for administering other drugs

7. LARGE VOLUME PARENTERAL MARKET BY PACKAGING CONTAINER

7.1. Introduction

7.2. Correction of electrolyte & fluid balance disturbances

7.3. Nutrition

7.4. Vehicle for administering other drugs

8.  LARGE VOLUME PARENTERAL MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Volume

8.2.2. By Application

8.2.3. By Packaging Container

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Volume

8.3.2. By Application

8.3.3. By Packaging Container

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Volume

8.4.2. By Application

8.4.3. By Packaging Container

8.4.4. By Country

8.4.4.1. UK

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Italy

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Volume

8.5.2. By Application

8.5.3. By Packaging Container

8.5.4. By Country

8.5.4.1. UAE

8.5.4.2. Israel

8.5.4.3. Saudi Arabia

8.5.4.4. Others

8.6. Asia Pacific

8.6.1. By Volume

8.6.2. By Application

8.6.3. By Packaging Container

8.6.4. By Country

8.6.4.1. Japan

8.6.4.2. China

8.6.4.3. India

8.6.4.4. South Korea

8.6.4.5. Taiwan

8.6.4.6. Thailand

8.6.4.7. Indonesia

8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Fresenius Kabi AG

10.2. Albert David Ltd.

10.3. Otsuka Holdings Co., Ltd.

10.4. Grifols S.A.

10.5. B. Braun Melsungen AG

10.6. BML Parenteral Drugs

10.7. Akums Drugs & Pharmaceuticals Ltd.

10.8. DJ Labs

10.9. Parenteral Drugs (India) Limited

10.10. BKRS Pharma Pvt. Ltd.

10.11. Pfizer.

10.12. Baxter.

10.13. August Services 

10.14. INCOG BioPharma Services

10.15. Simtra BioPharma Solutions

Fresenius Kabi AG

Albert David Ltd.

Otsuka Holdings Co., Ltd.

Grifols S.A.

B. Braun Melsungen AG

BML Parenteral Drugs

Akums Drugs & Pharmaceuticals Ltd.

DJ Labs

Parenteral Drugs (India) Limited

BKRS Pharma Pvt. Ltd.

Pfizer.

Baxter.

August Bioservices 

INCOG BioPharma Services

Simtra BioPharma Solutions